Arts

Books

Fashion & Beauty

Performing Arts

Food

Visual Arts

Design

Business

Entrepreneurship

Investing

Marketing

Careers

Management

Non-Profit

Comedy

Stand-Up

Comedy Interviews

Improv

Education

Self-Improvement

How To

Courses

Language Learning

Fiction

Comedy Fiction

Drama

Science Fiction

Government

Health & Fitness

Medicine

Alternative Health

Nutrition

Mental Health

Fitness

Sexuality

History

Kids & Family

Parenting

Stories for Kids

Education for Kids

Pets & Animals

Leisure

Video Games

Games

Automotive

Animation & Manga

Hobbies

Aviation

Home & Garden

Crafts

Music

Music Commentary

Music Interviews

Music History

News

Sports News

Entertainment News

News Commentary

Politics

Daily News

Business News

Tech News

Religion & Spirituality

Christianity

Spirituality

Religion

Judaism

Islam

Buddhism

Hinduism

Science

Social Sciences

Life Sciences

Natural Sciences

Nature

Chemistry

Mathematics

Earth Sciences

Physics

Astronomy

Society & Culture

Documentary

Relationships

Philosophy

Personal Journals

Places & Travel

Sports

Golf

Soccer

Wrestling

Basketball

Football

Fantasy Sports

Baseball

Wilderness

Running

Hockey

Rugby

Cricket

Volleyball

Tennis

Swimming

Technology

True Crime

TV & Film

Film Interviews

TV Reviews

After Shows

Film Reviews

Film History

EDO MONTREAL Greek Podcast at Radio Centre-Ville 102.3 FM

EDO Montreal

मैं जगदेव सिंह फोगाट, स्वागत करता हूं आपका मेरे पोडकास्ट चैनल " चर्चा में " । दोस्तों यहां आप हर हफ्ते बहुचर्चित विषयों पर तैयार की गई डिटेल रिपोर्ट सुन सकेंगे । so wish you all happy listening.......

चर्चा में (Jagdev Phogaat)

El Derecho Penal tiene su espacio en La Voz del Derecho.

CRIMEN Y DERECHO

The SDxCentral Weekly Wrap podcast provides you with a way to easily and quickly catch-up on the top next-generation IT infrastructure developments from the week. In this three to five minute podcast, we cover the week's major news stories around topics such as SD-WAN, 5G, the Internet of Things, AI, Network Security, Containers, Software Defined Networking, Network Function Virtualization, Data Centers, Storage, and Network and Application Performance Management. Subscribe today to never miss an episode and visit an episode's webpage for more details on the week’s stories. Got feedback? Send it to podcasts@sdxcentral.com

SDxCentral Weekly Wrap

It’s risky speaking out AGAINST Scientology! Their leader and founder (L. Ron Hubbard ) instructs them to destroy anyone that does.  The members will only listen and obey their god or face consequences themselves. It all began in 1974 for me.  I was 7 and my sister 5. My mother was seeking help in life trying to survive and she “found” this cult and began her own indoctrination. We didn’t have a choice and followed her lead.  This podcast is a gathering of my memories sparked by photos or documents I’ve had over the years.  It’s all about speaking the TRUTH about what happened to me.I was raised by L. Ron Hubbard technically and I hope to join the hundreds (if not thousands) of other people that have escaped.

It’s risky speaking out AGAINST Scientology! Their leader and founder (L. Ron Hubbard ) instructs them to destroy anyone that does. The members will only listen and obey their god or face consequences themselves. It all began in 1974 for me. I was 7 and my sister 5. My mother was seeking help in life trying to survive and she “found” this cult and began her own indoctrination. We didn’t have a choice and followed her lead. This podcast is a gathering of my memories sparked by photos or documents I’ve had over the years. It’s all about speaking the TRUTH about what happened to me.I was raised by L. Ron Hubbard technically and I hope to join the hundreds (if not thousands) of other people that have escaped.

Four Decades In Scientology

Take a 10 minute break to catch up on weekly Messiah news, culture trends, and top songs. Pulse Rewind features breaking news on campus, as well as global events. Tune in every Monday to stay updated.

Pulse Rewind

“My Thoughts” is the audio version of my column. Past topics include: My Father, Common Decency, Racism, Friendship, and profiles of such interesting people such as David Geschke, Jordan Peterson,  and Greta Thunberg.  My column can be found at Jeffrey.McAndrew.wordpress.com.

“My Thoughts” is the audio version of my column. Past topics include: My Father, Common Decency, Racism, Friendship, and profiles of such interesting people such as David Geschke, Jordan Peterson, and Greta Thunberg. My column can be found at Jeffrey.McAndrew.wordpress.com.

My Thoughts with Jeffrey McAndrew

Comentarios y opiniones electorales de México y el mundo, en lo municipal, estatal y federal, con invitados expertos que brinden al público opiniones bien informadas del acontecer electoral.

Mundo Electoral

Hey All,
My passion for Audio Recording landed me here at a Podcast Platform.
And I love podcasting.

Listen to the stories, events and instances happening around me.

Hey All, My passion for Audio Recording landed me here at a Podcast Platform. And I love podcasting. Listen to the stories, events and instances happening around me.

Solanki's Podcast

QUE PASARIA SI LA TECNOLOGIA FALLA EN LA ACTUALIDAD. PROS Y CONTRAS

Area69 Online

Podcast by Жандос Кашкимбаев

Voice of Kazakhstan

世界に日陰者を増やすため、神的存在の「カミS」の司令に「闇枝ちゃん」と6人のエージェントが挑むラジオ番組。
FMながおかにて毎月第1第3金曜日 24:00より放送中。

世界に日陰者を増やすため、神的存在の「カミS」の司令に「闇枝ちゃん」と6人のエージェントが挑むラジオ番組。 FMながおかにて毎月第1第3金曜日 24:00より放送中。

秘密結社HIKAGEのどんより酒場

A collection of news stories relevant to the Filipinos around the world. This includes news reports from the largest networks and broadsheets, interviews, opinion and reactions with reporters, newsmakers, experts and the man on the street. The Filipino News Podcast is hosted and delivered by Chinggay Andrada.

Filipino News Podcast

A Pod where I talk about daily news, what's going on in my life, and all anime, music, video game stuff.

It Does It Podcast

The louieworkemail's Podcast

Op papier heeft iedereen mensenrechten, maar hoe ziet dit in de praktijk eruit? In de podcast Het Vraagstuk gaat <a href="https://www.davidachterdemolen.com/hetpodcastkantoor" rel="noopener noreferrer" target="_blank">David Achter de Molen</a> in gesprek met ervaringsdeskundigen en experts om antwoord te krijgen op complexe vraagstukken. Het College voor de Rechten van de Mens belicht, beschermt en bevordert de mensenrechten in Nederland. Wil je meer informatie over mensenrechten of wil je melding maken van discriminatie? Ga dan naar <a href="mensenrechten.nl" rel="noopener noreferrer" target="_blank">mensenrechten.nl</a>.

Op papier heeft iedereen mensenrechten, maar hoe ziet dit in de praktijk eruit? In de podcast Het Vraagstuk gaat David Achter de Molen in gesprek met ervaringsdeskundigen en experts om antwoord te krijgen op complexe vraagstukken. Het College voor de Rechten van de Mens belicht, beschermt en bevordert de mensenrechten in Nederland. Wil je meer informatie over mensenrechten of wil je melding maken van discriminatie? Ga dan naar mensenrechten.nl.

Op papier heeft iedereen mensenrechten, maar hoe ziet dit in de praktijk eruit? In de podcast Het Vraagstuk gaat <a href="https://www.davidachterdemolen.com/hetpodcastkantoor" rel="noopener noreferrer">David Achter de Molen</a> in gesprek met ervaringsdeskundigen en experts om antwoord te krijgen op complexe vraagstukken. Het College voor de Rechten van de Mens belicht, beschermt en bevordert de mensenrechten in Nederland. Wil je meer informatie over mensenrechten of wil je melding maken van discriminatie? Ga dan naar <a href="mensenrechten.nl" rel="noopener noreferrer">mensenrechten.nl</a>.

Het Vraagstuk

Big 12 and Baylor college basketball talk — men and women — every week with Zach Smith&nbsp;and Brice Cherry of the Waco Tribune-Herald. We never mail it in. <hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

Big 12 and Baylor college basketball talk — men and women — every week with Zach Smith and Brice Cherry of the Waco Tribune-Herald. We never mail it in. Hosted on Acast. See acast.com/privacy for more information.

Big 12 and Baylor college basketball talk — men and women — every week with Zach Smith&nbsp;and Brice Cherry of the Waco Tribune-Herald. We never mail it in. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Top 25 Voter Pod

Comune di Milano, piazza della Scala, 2 - 20121 Milano - Italia

Comune di Milano

Battering Ram Tavern is a podcast designed to break the societal restraints by highlighting and discussing political and social issues, race, religion, history, ancient mysteries and much more. You know, those conversations you aren&#39;t suppose to have at the dinner table... this podcast breaks that rule!

Battering Ram Tavern is a podcast designed to break the societal restraints by highlighting and discussing political and social issues, race, religion, history, ancient mysteries and much more. You know, those conversations you aren't suppose to have at the dinner table... this podcast breaks that rule!

Battering Ram Tavern is a podcast designed to break the societal restraints by highlighting and discussing political and social issues, race, religion, history, ancient mysteries and much more. You know, those conversations you aren't suppose to have at the dinner table... this podcast breaks that rule!

Battering Ram Tavern

Wer mit wem? Das ist die Frage bei „Handelsblatt Deals – dem M&A Podcast“. Hier geht es alle zwei Wochen um das, was die Wirtschaftswelt gerade bewegt: Welche Unternehmen sich annähern, welche Deals aktuell verhandelt werden und welche Wendungen Wirtschaftsinteressierte im Blick behalten sollten.

Handelsblatt-Redakteurin Nele Dohmen spricht mit Gästen über aktuelle Fusionen, Übernahmen, Börsengänge und Finanzierungen.

Wer mit wem? Das ist die Frage bei „Handelsblatt Deals – dem M&A Podcast“. Hier geht es alle zwei Wochen um das, was die Wirtschaftswelt gerade bewegt: Welche Unternehmen sich annähern, welche Deals aktuell verhandelt werden und welche Wendungen Wirtschaftsinteressierte im Blick behalten sollten. Handelsblatt-Redakteurin Nele Dohmen spricht mit Gästen über aktuelle Fusionen, Übernahmen, Börsengänge und Finanzierungen.

Wer mit wem? Das ist die Frage bei „Handelsblatt Deals – dem M&amp;A Podcast“. Hier geht es alle zwei Wochen um das, was die Wirtschaftswelt gerade bewegt: Welche Unternehmen sich annähern, welche Deals aktuell verhandelt werden und welche Wendungen Wirtschaftsinteressierte im Blick behalten sollten.

Handelsblatt-Redakteurin Nele Dohmen spricht mit Gästen über aktuelle Fusionen, Übernahmen, Börsengänge und Finanzierungen.

Handelsblatt Deals - der M&A Podcast

Podcast informativo para compartir historias y anécdotas más allá de las canchas durante el Mundial de Fútbol, Qatar 2022. Comentarios, consejos, entrevistas y mucho más durante la fiesta mundialística desde Qatar.

Cortita y al pie, podcast de la VOA en Qatar - Voz de América

If you're looking for a podcast that brings energy, personality, and a fresh perspective, then The Chop Up is where it's at. Hosted by the dynamic duo of Sterling Furrowh and JSpenceTheKing, this show is all about diving into the hot topics and big stories surrounding the music and sports world. Sterling and Spence bring a blend of humor, insight, and straight-up real talk that makes every episode a blast. Whether they’re breaking down key match-ups, debating player performances, or just chopping it up about the latest sports news, their chemistry and passion for the game is contagious. The Chop Up is the perfect mix of fun, music, and sports, making it a must-listen! The Chop Up with JSpenceTheKing and Sterling Furrowh - Wednesday at 9:00 p.m. EST.
The Chop Up is on all Rumblings social media, vidcast, and podcast platforms. Follow them on Twitter @FurrowhSterling, @JSpenceTheKing!

If you're looking for a podcast that brings energy, personality, and a fresh perspective, then The Chop Up is where it's at. Hosted by the dynamic duo of Sterling Furrowh and JSpenceTheKing, this show is all about diving into the hot topics and big stories surrounding the music and sports world. Sterling and Spence bring a blend of humor, insight, and straight-up real talk that makes every episode a blast. Whether they’re breaking down key match-ups, debating player performances, or just chopping it up about the latest sports news, their chemistry and passion for the game is contagious. The Chop Up is the perfect mix of fun, music, and sports, making it a must-listen! The Chop Up with JSpenceTheKing and Sterling Furrowh - Wednesday at 9:00 p.m. EST. The Chop Up is on all Rumblings social media, vidcast, and podcast platforms. Follow them on Twitter @FurrowhSterling, @JSpenceTheKing!

The Chop Up

El feminisme ha aconseguit victòries importants els darrers anys, victòries que també han donat peu a debats dins del moviment i que han comportat alguns canvis socials que encara es paeixen. Al pòdcast Quarta Onada volem parlar de com s'han aconseguit aquestes victòries i sobretot de quines han de ser les pròximes en un àmbit molt central: el de la llibertat sexual.

En diversos episodis repassarem les conseqüències de casos mediàtics com el de Gisèle Pelicot, el de Dani Alves o el de la Manada, i ens demanarem quina mena de coses han canviat en el dia a dia, quins efectes té el nou prisma sobre la llibertat sexual femenina en les relacions entre homes i dones i quins debats socials i entre feministes s'han obert o continuat.

El feminisme ha aconseguit victòries importants els darrers anys, victòries que també han donat peu a debats dins del moviment i que han comportat alguns canvis socials que encara es paeixen. Al pòdcast Quarta Onada volem parlar de com s'han aconseguit aquestes victòries i sobretot de quines han de ser les pròximes en un àmbit molt central: el de la llibertat sexual. En diversos episodis repassarem les conseqüències de casos mediàtics com el de Gisèle Pelicot, el de Dani Alves o el de la Manada, i ens demanarem quina mena de coses han canviat en el dia a dia, quins efectes té el nou prisma sobre la llibertat sexual femenina en les relacions entre homes i dones i quins debats socials i entre feministes s'han obert o continuat.

El feminisme ha aconseguit victòries importants els darrers anys, victòries que també han donat peu a debats dins del moviment i que han comportat alguns canvis socials que encara es paeixen. Al pòdcast&nbsp;Quarta Onada volem parlar de com s'han aconseguit aquestes victòries i sobretot de quines han de ser les pròximes en un àmbit molt central: el de la llibertat sexual.

En diversos episodis repassarem les conseqüències de casos mediàtics com el de Gisèle Pelicot, el de Dani Alves&nbsp;o el de la Manada, i ens demanarem quina mena de coses han canviat en el dia a dia, quins efectes té el nou prisma sobre la llibertat sexual femenina en les relacions entre homes i dones i quins debats socials i entre feministes s'han obert o continuat.

Quarta onada

【金銭的なレバレッジだけでなく、不動産を持つことで時間や人脈等ができていく】 私は20代の時にビジネススクールの講師や地元密着型の薬局の経営などに携わってきました。 その当時、幅広い年齢層の方々と出会う中で、不動産を活用して豊かな人生を過ごす人と不動産を十分に活用できず、無計画のまま老後を迎え生活が苦しい人を何人も見てきました。 若いうちから不動産に対する知見を高め有効に活用した方が悠々自的な過ごし方ができるのではないかと思い20代後半に大家になることを心ざしました。 その後は猛勉強を重ねて晴れて大家になると金銭だけでなく、時間の余裕やたくさんの人との出会いも恵まれる経験を積むことができました。 一方で、改めて町を見渡してみると画一的な住居ばかりが溢れており住む人の暮らしが十分に考えられていないと実感しました。 こうした背景から、私は「人生で一番長い時間を過ごす住居を幸せな空間にして、幸せと感じていただける人を増やしたい」と思って経営をしています。 理念を感じるアパート経営をテーマに、人生で1番長い時間を過ごす住居を幸せな空間にするために「ペットと共生できる専用住居」や「子育て世代が幸せに過ごせる住居」「住むだけでワクワクするような住居」を構想中です。 この他にもゆとりある暮らしのための不動産を通した資産形成、空き家や土地の有効活用のお手伝いをしておりますので、当番組を通じてこれまで多くのお客様より不動産について受けたご質問等をベースにいろいろな情報を発信していきたいと思います！ 動画: https://youtu.be/i68K7ksvJtg LINE公式: https://lin.ee/Vrj61rR

【金銭的なレバレッジだけでなく、不動産を持つことで時間や人脈等ができていく】 私は20代の時にビジネススクールの講師や地元密着型の薬局の経営などに携わってきました。 その当時、幅広い年齢層の方々と出会う中で、不動産を活用して豊かな人生を過ごす人と不動産を十分に活用できず、無計画のまま老後を迎え生活が苦しい人を何人も見てきました。 若いうちから不動産に対する知見を高め有効に活用した方が悠々自的な過ごし方ができるのではないかと思い20代後半に大家になることを心ざしました。 その後は猛勉強を重ねて晴れて大家になると金銭だけでなく、時間の余裕やたくさんの人との出会いも恵まれる経験を積むことができました。 一方で、改めて町を見渡してみると画一的な住居ばかりが溢れており住む人の暮らしが十分に考えられていないと実感しました。 こうした背景から、私は「人生で一番長い時間を過ごす住居を幸せな空間にして、幸せと感じていただける人を増やしたい」と思って経営をしています。 理念を感じるアパート経営をテーマに、人生で1番長い時間を過ごす住居を幸せな空間にするために「ペットと共生できる専用住居」や「子育て世代が幸せに過ごせる住居」「住むだけでワクワクするような住居」を構想中です。 この他にもゆとりある暮らしのための不動産を通した資産形成、空き家や土地の有効活用のお手伝いをしておりますので、当番組を通じてこれまで多くのお客様より不動産について受けたご質問等をベースにいろいろな情報を発信していきたいと思います！ 動画: https://youtu.be/i68K7ksvJtg LINE公式: https://lin.ee/Vrj61rR

【金銭的なレバレッジだけでなく、不動産を持つことで時間や人脈等ができていく】 私は20代の時にビジネススクールの講師や地元密着型の薬局の経営などに携わってきました。 その当時、幅広い年齢層の方々と出会う中で、不動産を活用して豊かな人生を過ごす人と不動産を十分に活用できず、無計画のまま老後を迎え生活が苦しい人を何人も見てきました。 若いうちから不動産に対する知見を高め有効に活用した方が悠々自的な過ごし方ができるのではないかと思い20代後半に大家になることを心ざしました。 その後は猛勉強を重ねて晴れて大家になると金銭だけでなく、時間の余裕やたくさんの人との出会いも恵まれる経験を積むことができました。 一方で、改めて町を見渡してみると画一的な住居ばかりが溢れており住む人の暮らしが十分に考えられていないと実感しました。 こうした背景から、私は「人生で一番長い時間を過ごす住居を幸せな空間にして、幸せと感じていただける人を増やしたい」と思って経営をしています。 理念を感じるアパート経営をテーマに、人生で1番長い時間を過ごす住居を幸せな空間にするために「ペットと共生できる専用住居」や「子育て世代が幸せに過ごせる住居」「住むだけでワクワクするような住居」を構想中です。 この他にもゆとりある暮らしのための不動産を通した資産形成、空き家や土地の有効活用のお手伝いをしておりますので、当番組を通じてこれまで多くのお客様より不動産について受けたご質問等をベースにいろいろな情報を発信していきたいと思います！ 動画: https://youtu.be/i68K7ksvJtg LINE公式: https://lin.ee/Vrj61rR

業界泣かせの正直不動産～不動産投資で人生に最大のレバレッジを～

Welcome to In Layman’s Terms, the podcast where host Guy Norah takes complex ideas and transforms them into clear, digestible conversations for everyone. Each episode invites expert guests from diverse fields, breaking down intricate topics—from business and technology to health, culture, and beyond—in a relatable and approachable way.

Whether you’re looking to gain fresh insights, demystify difficult concepts, or simply stay curious about the world around you, Guy and his guests have you covered. No jargon, no confusion—just thoughtful conversations made simple.

Subscribe now and start seeing the complicated clearly.

Welcome to In Layman’s Terms, the podcast where host Guy Norah takes complex ideas and transforms them into clear, digestible conversations for everyone. Each episode invites expert guests from diverse fields, breaking down intricate topics—from business and technology to health, culture, and beyond—in a relatable and approachable way. Whether you’re looking to gain fresh insights, demystify difficult concepts, or simply stay curious about the world around you, Guy and his guests have you covered. No jargon, no confusion—just thoughtful conversations made simple. Subscribe now and start seeing the complicated clearly.

In Layman’s Terms with Guy Nohra

This is not a news recap. This is what happens when you strip the narrative away and look at the damage underneath.Every week we break down leadership, decisions, and the consequences no one wants to own. The incompetence, the contradictions, and the moments where systems start to fail in real time.No spin. No protection. No pretending this is normal.Just a clear look at power, how it is being used, and what it is costing.

This is not a news recap. This is what happens when you strip the narrative away and look at the damage underneath. Every week we break down leadership, decisions, and the consequences no one wants to own. The incompetence, the contradictions, and the moments where systems start to fail in real time. No spin. No protection. No pretending this is normal. Just a clear look at power, how it is being used, and what it is costing.

BlueBird on Your Shoulder

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

Malaria Vaccine

Retrouvez nos rendez-vous culturelsHébergé par Audiomeans. Visitez <a href="https://www.audiomeans.fr/politique-de-confidentialite">audiomeans.fr/politique-de-confidentialite</a> pour plus d'informations.

Retrouvez nos rendez-vous culturels Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Retrouvez nos rendez-vous culturelsHébergé par Audiomeans. Visitez <a href="https://www.audiomeans.fr/politique-de-confidentialite" rel="noopener noreferrer">audiomeans.fr/politique-de-confidentialite</a> pour plus d'informations.

Demandez le programme

The Cigar Politico

Soy City Buzz

Florida State News Tracker" Florida State News Tracker" brings you the latest updates on politics, economy, education, sports, and local events in Florida. Stay informed with news from the Sunshine State.

Florida State News Tracker"Florida State News Tracker" brings you the latest updates on politics, economy, education, sports, and local events in Florida. Stay informed with news from the Sunshine State.

Florida State News Tracker" Florida State News Tracker" brings you the latest updates on politics, economy, education, sports, and local events in Florida. Stay informed with news from the Sunshine State.

Florida State News and Info Tracker

[DAILY] Crypto News, AI News, and maybe stock market News shortly. These trends are taking off, You can get in early to profit!

Let’s chill and get rich together. 😉 | 

🔴 Collaboration inquiries: gorichfire@gmail.com | 

🔥 Daily news updates posted in X, search “Rich Compass” or click: https://lihi2.com/hZ6x3

[DAILY] Crypto News, AI News, and maybe stock market News shortly. These trends are taking off, You can get in early to profit! Let’s chill and get rich together. 😉 | 🔴 Collaboration inquiries: gorichfire@gmail.com | 🔥 Daily news updates posted in X, search “Rich Compass” or click: https://lihi2.com/hZ6x3

Rich Compass

Io Riparto è una produzione OIKO che si pone come obiettivo la diffusione della cultura digitale in ogni settore della vita del Paese. Coinvolgiamo in questo progetto esponenti di rilievo del mondo economico, sociale e imprenditoriale, attraverso il format Live Lab. I Live Lab sono gli eventi online di Io Riparto, incontri agili e articolati, ospitati sulla piattaforma eventi dedicata, in cui i talker, nei 300 secondi a loro disposizione, espongono punti di vista e spunti di riflessione su argomenti che gravitano attorno al mondo della trasformazione digitale. Il Data Journalist de il Sole 24 Ore Luca Tremolada e la Tech &amp; Innovation blogger Barbara Gasperini accolgono gli ospiti nello studio virtuale e interagiscono con la Community di Io Riparto sulla piattaforma di eventi digitali, in uno scambio proficuo di idee e informazioni.

Io Riparto è una produzione OIKO che si pone come obiettivo la diffusione della cultura digitale in ogni settore della vita del Paese. Coinvolgiamo in questo progetto esponenti di rilievo del mondo economico, sociale e imprenditoriale, attraverso il format Live Lab. I Live Lab sono gli eventi online di Io Riparto, incontri agili e articolati, ospitati sulla piattaforma eventi dedicata, in cui i talker, nei 300 secondi a loro disposizione, espongono punti di vista e spunti di riflessione su argomenti che gravitano attorno al mondo della trasformazione digitale. Il Data Journalist de il Sole 24 Ore Luca Tremolada e la Tech & Innovation blogger Barbara Gasperini accolgono gli ospiti nello studio virtuale e interagiscono con la Community di Io Riparto sulla piattaforma di eventi digitali, in uno scambio proficuo di idee e informazioni.

Io Riparto

Welcome to Tav's Headline News Reviews! Podcast&nbsp; Dive into the world of news with "Tav's Headline News Reviews," where we bring you reviews of this week’s news stories that you should be aware of in the world. Our goal is to provide you with a quick snapshot of news items that you should know. Don't forget to like, subscribe, and share your thoughts in the comments! My YOUTUBE CHANNEL LINK: https://www.youtube.com/@TavsHeadlineNewsReviews MY PODCAST LINK: https://tavsheadlinenewsreviews.buzzsprout.com My TWITTER/X LINK: https://x.com/TavsNewsReviews My FACEBOOK LINK: https://www.facebook.com/profile.php?id=61576891084536

Welcome to Tav's Headline News Reviews! Podcast  Dive into the world of news with "Tav's Headline News Reviews," where we bring you reviews of this week’s news stories that you should be aware of in the world. Our goal is to provide you with a quick snapshot of news items that you should know. Don't forget to like, subscribe, and share your thoughts in the comments! My YOUTUBE CHANNEL LINK: https://www.youtube.com/@TavsHeadlineNewsReviews MY PODCAST LINK: https://tavsheadlinenewsreviews.buzzsprout.com My TWITTER/X LINK: https://x.com/TavsNewsReviews My FACEBOOK LINK: https://www.facebook.com/profile.php?id=61576891084536

News Podcasts / Page 1298

EDO Montreal

चर्चा में (Jagdev Phogaat)

CRIMEN Y DERECHO

SDxCentral Weekly Wrap

Four Decades In Scientology

Pulse Rewind

My Thoughts with Jeffrey McAndrew

Mundo Electoral

Solanki's Podcast

Area69 Online

Voice of Kazakhstan

秘密結社HIKAGEのどんより酒場

Filipino News Podcast

It Does It Podcast

The louieworkemail's Podcast

Het Vraagstuk

Top 25 Voter Pod

Comune di Milano

Battering Ram Tavern

Handelsblatt Deals - der M&A Podcast

Cortita y al pie, podcast de la VOA en Qatar - Voz de América

The Chop Up

Quarta onada

業界泣かせの正直不動産～不動産投資で人生に最大のレバレッジを～

In Layman’s Terms with Guy Nohra

BlueBird on Your Shoulder

Malaria Vaccine

Demandez le programme

The Cigar Politico

Soy City Buzz

Florida State News and Info Tracker

Rich Compass

Io Riparto

Tav's Headline News Reviews

C'est tout com'

CANCL ME LATER!

EN DIRECTO CON NELSON RUBIO

Blockchain Beyond Crypto

The American Legal Record

Duff Johnson

The HopTake by HopNews

Ράδιο FreeMinder

ドローンラジオ 〜ドローンビジネスニュースと裏話〜

3oh3

Going Disparate: Politics and Crime with Pam and Mara

Teorías II R.I

What do we do next?

Former Member

The Casual Politics Podcast

Slave Is a Slave

ドローンラジオ　〜ドローンビジネスニュースと裏話〜